X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2403) 2403
Book Review (186) 186
Publication (69) 69
Newsletter (5) 5
Book Chapter (2) 2
Conference Proceeding (2) 2
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2254) 2254
humans (1878) 1878
carmustine - administration & dosage (1600) 1600
male (1351) 1351
female (1321) 1321
middle aged (1109) 1109
adult (1062) 1062
antineoplastic combined chemotherapy protocols - therapeutic use (960) 960
oncology (843) 843
aged (678) 678
chemotherapy (601) 601
animals (589) 589
combined modality therapy (575) 575
cyclophosphamide - administration & dosage (521) 521
carmustine - therapeutic use (515) 515
brain neoplasms - drug therapy (495) 495
melphalan - administration & dosage (424) 424
carmustine (421) 421
etoposide - administration & dosage (414) 414
carmustine - adverse effects (400) 400
antineoplastic combined chemotherapy protocols - adverse effects (386) 386
hematology (368) 368
cytarabine - administration & dosage (356) 356
adolescent (346) 346
treatment outcome (344) 344
antineoplastic combined chemotherapy protocols - administration & dosage (339) 339
transplantation, autologous (315) 315
vincristine - administration & dosage (313) 313
mice (305) 305
abridged index medicus (298) 298
cisplatin - administration & dosage (285) 285
glioma - drug therapy (271) 271
cancer (268) 268
transplantation (258) 258
antineoplastic agents - administration & dosage (246) 246
prognosis (242) 242
survival analysis (240) 240
doxorubicin - administration & dosage (234) 234
therapy (234) 234
rats (225) 225
survival rate (225) 225
antineoplastic agents, alkylating - administration & dosage (222) 222
bcnu (222) 222
time factors (222) 222
bone marrow transplantation (220) 220
prednisone - administration & dosage (220) 220
carmustine - pharmacology (216) 216
drug therapy, combination (209) 209
hematopoietic stem cell transplantation (209) 209
glioblastoma - drug therapy (203) 203
disease-free survival (199) 199
clinical neurology (191) 191
dose-response relationship, drug (182) 182
drug administration schedule (176) 176
follow-up studies (175) 175
cyclophosphamide (172) 172
retrospective studies (172) 172
bone-marrow transplantation (171) 171
radiotherapy (171) 171
remission induction (168) 168
immunology (167) 167
dacarbazine - administration & dosage (166) 166
antineoplastic agents - therapeutic use (164) 164
etoposide (163) 163
hodgkin disease - drug therapy (147) 147
malignant glioma (146) 146
survival (142) 142
brain neoplasms - radiotherapy (138) 138
hodgkin disease - therapy (138) 138
glioblastoma (136) 136
medicine & public health (134) 134
melanoma - drug therapy (132) 132
multiple myeloma - drug therapy (132) 132
pharmacology & pharmacy (127) 127
surgery (127) 127
child (126) 126
high-dose chemotherapy (126) 126
recurrence (126) 126
clinical trials as topic (124) 124
prospective studies (124) 124
antineoplastic agents, alkylating - therapeutic use (122) 122
care and treatment (122) 122
temozolomide (120) 120
brain neoplasms - pathology (119) 119
lymphoma, non-hodgkin - drug therapy (119) 119
brain neoplasms - surgery (118) 118
trial (118) 118
gliomas (116) 116
lymphoma, non-hodgkin - therapy (115) 115
salvage therapy (110) 110
non-hodgkins-lymphoma (108) 108
stem cells (108) 108
methotrexate - administration & dosage (107) 107
carmustine - toxicity (106) 106
cisplatin (106) 106
dexamethasone - administration & dosage (104) 104
brain neoplasms - therapy (103) 103
cyclophosphamide - therapeutic use (103) 103
neoplasm transplantation (100) 100
brain neoplasms - mortality (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2277) 2277
German (24) 24
Russian (22) 22
Spanish (21) 21
Japanese (18) 18
French (17) 17
Chinese (9) 9
Polish (9) 9
Italian (7) 7
Czech (2) 2
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 8, pp. dju170 - dju170
This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field... 
SURVIVAL | OUTCOMES | ONCOLOGY | STEM-CELL TRANSPLANTATION | CHOP PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Primary Myelofibrosis | Nitrogen Mustard Compounds - administration & dosage | Humans | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Melphalan - adverse effects | Vincristine - administration & dosage | Boronic Acids - administration & dosage | Carmustine - adverse effects | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Bortezomib | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Etoposide - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Melphalan - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2001, Volume 98, Issue 10, pp. 2930 - 2934
Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD) after completed therapy, and the discrimination between active tumor... 
Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Hodgkin Disease - pathology | Humans | Salvage Therapy | Transplantation, Autologous | Life Tables | Vinblastine - administration & dosage | False Positive Reactions | Mediastinal Neoplasms - therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Radiopharmaceuticals | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Diagnosis, Differential | Prednisone - administration & dosage | Dexamethasone - administration & dosage | False Negative Reactions | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Bleomycin - administration & dosage | Mediastinal Neoplasms - diagnostic imaging | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Fibrosis | Fluorodeoxyglucose F18 | Tomography, Emission-Computed | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2008, Volume 112, Issue 10, pp. 4017 - 4023
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2012, Volume 158, Issue 3, pp. 355 - 362
Journal Article
Annals of Oncology, ISSN 0923-7534, 5/2008, Volume 19, Issue 5, pp. 958 - 963
Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young... 
Autologous stem-cell transplantation | Peripheral T-cell lymphoma | Prognosis | ALEMTUZUMAB | PROGNOSTIC-FACTORS | MARKER | NON-HODGKINS-LYMPHOMAS | peripheral T-cell lymphoma | GEL-TAMO EXPERIENCE | FRONT | MODEL | prognosis | FEATURES | ONCOLOGY | REAL CLASSIFICATION | autologous stem-cell transplantation | EXPRESSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Vincristine - administration & dosage | Adult | Female | Lymphoma, T-Cell, Peripheral - classification | Doxorubicin - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Neoplasms, Second Primary - epidemiology | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Vincristine - adverse effects | Lymphoma, T-Cell, Peripheral - surgery | Aged | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Doxorubicin - adverse effects | Carmustine - administration & dosage | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 327 - 336
We conducted a multicentre, phase II study of interim positron emission tomography ( PET ) as a guide to risk‐adapted therapy in high‐risk patients with newly... 
fluorodeoxyglucose positron emission tomography | lymphoma | autologous stem cell transplantation | Fluorodeoxyglucose positron emission tomography | Lymphoma | Autologous stem cell transplantation | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Positron-Emission Tomography | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Radiopharmaceuticals | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Kaplan-Meier Estimate | Rituximab | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18 | Aged | Fluorine Radioisotopes | Peripheral Blood Stem Cell Transplantation | Carmustine - administration & dosage | PET imaging | Care and treatment | Lymphomas | Index Medicus
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2005, Volume 16, Issue 1, pp. 116 - 123
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2006, Volume 24, Issue 6, pp. 929 - 936
Journal Article
Journal Article